Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

References

• Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA72(5), 1858–1862 (1975).
   PubMed Web of Science ®Google Scholar
• Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res.387(3), 271–280 (1986).
   PubMed Web of Science ®Google Scholar
• O’Farrell PZ, Goodman HM, O’Farrell PH. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell12(4), 1133–1141 (1977).
   PubMed Web of Science ®Google Scholar
• Ksiezak-Reding H, Binder LI, Yen SH. Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer’s disease brains with Alz 50 and Tau-1. J. Biol. Chem.263(17), 7948–7953 (1988).
   PubMedGoogle Scholar
• Janke C, Holzer M, Klose J, Arendt T. Distribution of isoforms of the microtubule-associated protein tau in grey and white matter areas of human brain: a two-dimensional gelelectrophoretic analysis. FEBS Lett.379(3), 222–226 (1996).
   PubMedGoogle Scholar
• Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for β-structure. J. Biol. Chem.269(39), 24290–24297 (1994).
   PubMed Web of Science ®Google Scholar
• Butler M, Shelanski ML. Microheterogeneity of microtubule-associated tau proteins is due to differences in phosphorylation. J. Neurochem.47(5), 1517–1522 (1986).
   PubMedGoogle Scholar
• Hanger DP, Byers HL, Wray S et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem.282(32), 23645–23654 (2007).
   PubMed Web of Science ®Google Scholar
• Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev.33(1), 95–130 (2000).
   PubMed Web of Science ®Google Scholar
• Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett.336(3), 417–424 (1993).
   PubMed Web of Science ®Google Scholar
• Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer’s disease? J. Cell Biol.132(3), 413–425 (1996).
   PubMed Web of Science ®Google Scholar
• Hamdane M, Delobel P, Sambo AV et al. Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem. Pharmacol.66(8), 1619–1625 (2003).
   PubMedGoogle Scholar
• Holzer M, Rodel L, Seeger G et al. Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology. Neuroscience105(4), 1041–1054 (2001).
   PubMedGoogle Scholar
• Buee-Scherrer V, Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett.515(1–3), 151–154 (2002).
   PubMed Web of Science ®Google Scholar
• Goedert M, Hasegawa M, Jakes R et al. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett.409(1), 57–62 (1997).
   PubMedGoogle Scholar
• Kitano-Takahashi M, Morita H, Kondo S et al. Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.63(Pt 7), 602–604 (2007).
   PubMedGoogle Scholar
• Sato S, Cerny RL, Buescher JL, Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J. Neurochem.98(5), 1573–1584 (2006).
   PubMed Web of Science ®Google Scholar
• Tomizawa K, Omori A, Ohtake A, Sato K, Takahashi M. Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. FEBS Lett.492(3), 221–227 (2001).
   PubMedGoogle Scholar
• Greenwood JA, Scott CW, Spreen RC, Caputo CB, Johnson GV. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine as the primary phosphate acceptor. J. Biol. Chem.269(6), 4373–4380 (1994).
   PubMedGoogle Scholar
• Woods YL, Cohen P, Becker W et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2B3e at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J.355(Pt 3), 609–615 (2001).
   PubMed Web of Science ®Google Scholar
• Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell89(2), 297–308 (1997).
   PubMed Web of Science ®Google Scholar
• Drewes G. MARKing tau for tangles and toxicity. Trends Biochem. Sci.29(10), 548–555 (2004).
   PubMed Web of Science ®Google Scholar
• Paudel HK. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J. Biol. Chem.272(3), 1777–1785 (1997).
   PubMedGoogle Scholar
• Sergeant N, Delacourte A, Buee L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta1739(2–3), 179–197 (2005).
   PubMed Web of Science ®Google Scholar
• Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett.147(1), 58–62 (1992).
   PubMed Web of Science ®Google Scholar
• Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol.167(1), 99–110 (2004).
   PubMed Web of Science ®Google Scholar
• Lee G, Thangavel R, Sharma VM et al. Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J. Neurosci.24(9), 2304–2312 (2004).
   PubMed Web of Science ®Google Scholar
• Williamson R, Scales T, Clark BR et al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-b peptide exposure: involvement of Src family protein kinases. J. Neurosci.22(1), 10–20 (2002).
   PubMed Web of Science ®Google Scholar
• Jenkins SM, Johnson GV. Tau complexes with phospholipase C-gamma in situ.Neuroreport9(1), 67–71 (1998).
   PubMedGoogle Scholar
• Hwang SC, Jhon DY, Bae YS, Kim JH, Rhee SG. Activation of phospholipase C-g by the concerted action of tau proteins and arachidonic acid. J. Biol. Chem.271(31), 18342–18349 (1996).
   PubMed Web of Science ®Google Scholar
• Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem.70, 281–312 (2001).
   PubMed Web of Science ®Google Scholar
• Houlden H, Johnson J, Gardner-Thorpe C et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat. Genet.39(12), 1434–1436 (2007).
   PubMedGoogle Scholar
• Haltiwanger RS, Busby S, Grove K et al. O-glycosylation of nuclear and cytoplasmic proteins: regulation analogous to phosphorylation? Biochem. Biophys. Res. Commun.231(2), 237–242 (1997).
   PubMedGoogle Scholar
• Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem.272(14), 9308–9315 (1997).
   PubMed Web of Science ®Google Scholar
• Hart GW, Housley MP, Slawson C. Cycling of O-linked b-N-acetylglucosamine on nucleocytoplasmic proteins. Nature446(7139), 1017–1022 (2007).
   PubMed Web of Science ®Google Scholar
• Dong DL, Xu ZS, Hart GW, Cleveland DW. Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H. J. Biol. Chem.271(34), 20845–20852 (1996).
   PubMed Web of Science ®Google Scholar
• Lefebvre T, Ferreira S, Dupont-Wallois L et al. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins – a role in nuclear localization. Biochim. Biophys. Acta1619(2), 167–176 (2003).
   PubMed Web of Science ®Google Scholar
• Lefebvre T, Caillet-Boudin ML, Buee L, Delacourte A, Michalski JC. O-GlcNAc glycosylation and neurological disorders. Adv. Exp. Med. Biol.535, 189–202 (2003).
   PubMedGoogle Scholar
• Landrieu I, Smet C, Wieruszeski JM et al. Exploring the molecular function of PIN1 by nuclear magnetic resonance. Curr. Protein Pept. Sci.7(3), 179–194 (2006).
   PubMedGoogle Scholar
• Lippens G, Landrieu I, Smet C. Molecular mechanisms of the phospho-dependent prolyl cis/trans isomerase Pin1. FEBS J.274(20), 5211–5222 (2007).
   PubMedGoogle Scholar
• Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature399(6738), 784–788 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou XZ, Kops O, Werner A et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell6(4), 873–883 (2000).
   PubMed Web of Science ®Google Scholar
• Galas MC, Dourlen P, Begard S et al. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J. Biol. Chem.281(28), 19296–19304 (2006).
   PubMedGoogle Scholar
• Hamdane M, Dourlen P, Bretteville A et al. Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol. Cell. Neurosci.32(1–2), 155–160 (2006).
   PubMedGoogle Scholar
• Dourlen P, Ando K, Hamdane M et al. The peptidyl prolyl cis/trans isomerase Pin1 downregulates the inhibitor of apoptosis protein survivin. Biochim. Biophys. Acta1773(9), 1428–1437 (2007).
   PubMedGoogle Scholar
• Sultana R, Boyd-Kimball D, Poon HF et al. Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging27(11), 1564–1576 (2006).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Poon HF, St Clair D et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol. Dis.22(2), 223–232 (2006).
   PubMed Web of Science ®Google Scholar
• Thorpe JR, Morley SJ, Rulten SL. Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as a probe of its phosphorylated target proteins. Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer’s diseased brain. J. Histochem. Cytochem.49(1), 97–108 (2001).
   PubMedGoogle Scholar
• Holzer M, Gartner U, Stobe A et al. Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus. Acta Neuropathol.104(5), 471–481 (2002).
   PubMedGoogle Scholar
• Ramakrishnan P, Dickson DW, Davies P. Pin1 colocalization with phosphorylated tau in Alzheimer’s disease and other tauopathies. Neurobiol. Dis.14(2), 251–264 (2003).
   PubMedGoogle Scholar
• Thorpe JR, Mosaheb S, Hashemzadeh-Bonehi L et al. Shortfalls in the peptidyl-prolyl cis–trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias. Neurobiol. Dis.17(2), 237–249 (2004).
   PubMed Web of Science ®Google Scholar
• Brion JP, Couck AM, Passareiro E, Flament-Durand J. Neurofibrillary tangles of Alzheimer’s disease: an immunohistochemical study. J. Submicrosc. Cytol.17(1), 89–96 (1985).
   PubMedGoogle Scholar
• Delacourte A, Defossez A. Biochemical characterization of an immune serum which specifically marks neurons in neurofibrillary degeneration in Alzheimer’s disease. C. R. Acad. Sci. III Sci. Vie303(11), 439–444 (1986).
   PubMedGoogle Scholar
• Wischik CM, Novak M, Thogersen HC et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA85(12), 4506–4510 (1988).
   PubMed Web of Science ®Google Scholar
• Jakes R, Novak M, Davison M, Wischik CM. Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer’s disease. EMBO J.10(10), 2725–2729 (1991).
   PubMed Web of Science ®Google Scholar
• Kondo J, Honda T, Mori H et al. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron1(9), 827–834 (1988).
   PubMedGoogle Scholar
• Matsuo ES, Shin RW, Billingsley ML et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron13(4), 989–1002 (1994).
   PubMedGoogle Scholar
• Sergeant N, Bussiere T, Vermersch P, Lejeune JP, Delacourte A. Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. Neuroreport6(16), 2217–2220 (1995).
   PubMedGoogle Scholar
• Yoshida H, Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38δ or JNK2 in the presence of heparin generates the AT100 epitope. J. Neurochem.99(1), 154–164 (2006).
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Hasegawa M, Takio K et al. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron10(6), 1151–1160 (1993).
   PubMed Web of Science ®Google Scholar
• Mailliot C, Trojanowski JQ, Lee VM. Impaired tau protein function following nitration-induced oxidative stress in vitro and in vivo. Neurobiol. Aging23(1), S415–S415 (2002).
   Google Scholar
• Munch G, Kuhla B, Luth HJ, Arendt T, Robinson SR. Anti-AGEing defences against Alzheimer’s disease. Biochem. Soc. Trans.31(Pt 6), 1397–1399 (2003).
   PubMed Web of Science ®Google Scholar
• Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol. Rev.84(2), 361–384 (2004).
   PubMed Web of Science ®Google Scholar
• Delacourte A, Sergeant N, Buee L. Neurodegenerative Diseases: Tau Proteins in Neurodegenerative Diseases Other Than Alzheimer’s Disease (Therapy, MTiC Edition). Humana Press, NY, USA (2007).
   Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature442(7105), 916–919 (2006).
   PubMed Web of Science ®Google Scholar
• Cruts M, Gijselinck I, van der Zee J et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature442(7105), 920–924 (2006).
   PubMed Web of Science ®Google Scholar
• Delacourte A, Buee L. Normal and pathological Tau proteins as factors for microtubule assembly. Int. Rev. Cytol.171, 167–224 (1997).
   PubMedGoogle Scholar
• Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VM et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann. Neurol.49(2), 165–175 (2001).
   PubMed Web of Science ®Google Scholar
• Zhukareva V, Sundarraj S, Mann D et al. Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol.105(5), 469–476 (2003).
   PubMed Web of Science ®Google Scholar
• Forman MS, Trojanowski JQ, Lee VM. TDP-43: a novel neurodegenerative proteinopathy. Curr. Opin. Neurobiol.17(5), 548–555 (2007).
   PubMed Web of Science ®Google Scholar
• Sergeant N, David JP, Goedert M et al. Two-dimensional characterization of paired helical filament-tau from Alzheimer’s disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J. Neurochem.69(2), 834–844 (1997).
   PubMedGoogle Scholar
• Goedert M, Spillantini MG, Cairns NJ. Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron8(1), 159–168 (1992).
   PubMed Web of Science ®Google Scholar
• Sergeant N, David JP, Lefranc D et al. Different distribution of phosphorylated tau protein isoforms in Alzheimer’s and Pick’s diseases. FEBS Lett.412(3), 578–582 (1997).
   PubMedGoogle Scholar
• Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J. Neurochem.72(3), 1243–1249 (1999).
   PubMedGoogle Scholar
• Tolnay M, Sergeant N, Ghestem A et al. Argyrophilic grain disease and Alzheimer’s disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol.104(4), 425–434 (2002).
   PubMedGoogle Scholar
• Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogenous system degeneration”. Trans. Am. Neurol. Assoc.88, 25–29 (1963).
   PubMedGoogle Scholar
• Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol.10, 333–359 (1964).
   PubMed Web of Science ®Google Scholar
• Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans. Am. Neurol. Assoc.92, 23–26 (1967).
   PubMedGoogle Scholar
• Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch. Neurol.18(1), 20–33 (1968).
   PubMedGoogle Scholar
• Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci. Lett.76(1), 124–127 (1987).
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Bigio EH, Mackenzie IR et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol.114(1), 5–22 (2007).
   PubMed Web of Science ®Google Scholar
• Brion S, Plas J, Jeanneau A. Pick’s disease. Anatomo–clinical point of view. Rev. Neurol. (Paris)147(11), 693–704 (1991).
   PubMedGoogle Scholar
• Buee Scherrer V, Hof PR, Buee L et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathol.91(4), 351–359 (1996).
   PubMed Web of Science ®Google Scholar
• Delacourte A, Robitaille Y, Sergeant N et al. Specific pathological Tau protein variants characterize Pick’s disease. J. Neuropathol. Exp. Neurol.55(2), 159–168 (1996).
   PubMedGoogle Scholar
• Probst A, Tolnay M, Langui D, Goedert M, Spillantini MG. Pick’s disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol.92(6), 588–596 (1996).
   PubMedGoogle Scholar
• Mailliot C, Sergeant N, Bussiere T et al. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett.433(3), 201–204 (1998).
   PubMed Web of Science ®Google Scholar
• Harper PS, Reardon W. Heart disease in myotonic dystrophy. Lancet339(8798), 939 (1992).
   PubMedGoogle Scholar
• Reardon W, Harper PS. Advances in myotonic dystrophy: a clinical and genetic perspective. Curr. Opin. Neurol. Neurosurg.5(5), 605–609 (1992).
   PubMedGoogle Scholar
• Brook JD, McCurrach ME, Harley HG et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3´ end of a transcript encoding a protein kinase family member. Cell69(2), 385 (1992).
   PubMed Web of Science ®Google Scholar
• Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat. Genet.19(2), 196–198 (1998).
   PubMed Web of Science ®Google Scholar
• Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve23(12), 1789–1799 (2000).
   PubMedGoogle Scholar
• Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve36(3), 294–306 (2007).
   PubMed Web of Science ®Google Scholar
• Sansone V, Gandossini S, Cotelli M et al. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol. Sci.28(1), 9–15 (2007).
   PubMedGoogle Scholar
• Vermersch P, Sergeant N, Ruchoux MM et al. Specific tau variants in the brains of patients with myotonic dystrophy. Neurology47(3), 711–717 (1996).
   PubMed Web of Science ®Google Scholar
• Yoshimura N. Alzheimer’s neurofibrillary changes in the olfactory bulb in myotonic dystrophy. Clin. Neuropathol.9(5), 240–243 (1990).
   PubMedGoogle Scholar
• Yoshimura N, Otake M, Igarashi K et al. Topography of Alzheimer’s neurofibrillary change distribution in myotonic dystrophy. Clin. Neuropathol.9(5), 234–239 (1990).
   PubMedGoogle Scholar
• Sergeant N, Sablonniere B, Schraen-Maschke S et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum. Mol. Genet.10(19), 2143–2155 (2001).
   PubMed Web of Science ®Google Scholar
• Gomes-Pereira M, Foiry L, Nicole A et al. CTG trinucleotide repeat “big jumps”: large expansions, small mice. PLoS Genet.3(4), E52 (2007).
   PubMed Web of Science ®Google Scholar
• Seznec H, Agbulut O, Sergeant N et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum. Mol. Genet.10(23), 2717–2726 (2001).
   PubMedGoogle Scholar
• Maurage CA, Udd B, Ruchoux MM et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology65(10), 1636–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Hasegawa M, Takio K et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem.270(2), 823–829 (1995).
   PubMed Web of Science ®Google Scholar
• Derkinderen P, Scales TM, Hanger DP et al. Tyrosine 394 is phosphorylated in Alzheimer’s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci.25(28), 6584–6593 (2005).
   PubMedGoogle Scholar
• Ueda K, Masliah E, Saitoh T et al. Alz-50 recognizes a phosphorylated epitope of tau protein. J. Neurosci.10(10), 3295–3304 (1990).
   PubMedGoogle Scholar
• Lippens G, Wieruszeski JM, Leroy A et al. Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites. Chembiochem5(1), 73–78 (2004).
   PubMedGoogle Scholar
• Smet C, Leroy A, Sillen A et al. Accepting its random coil nature allows a partial NMR assignment of the neuronal Tau protein. Chembiochem5(12), 1639–1646 (2004).
   PubMedGoogle Scholar
• Lippens G, Sillen A, Smet C et al. Studying the natively unfolded neuronal Tau protein by solution NMR spectroscopy. Protein Pept. Lett.13(3), 235–246 (2006).
   PubMedGoogle Scholar
• Cleveland DW, Hwo SY, Kirschner MW. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol.116(2), 227–247 (1977).
   PubMed Web of Science ®Google Scholar
• Mandelkow E, Song YH, Schweers O, Marx A, Mandelkow EM. On the structure of microtubules, tau, and paired helical filaments. Neurobiol. Aging16(3), 347–354 (1995).
   PubMedGoogle Scholar
• Hoenger A, Gross H. Structural investigations into microtubule-MAP complexes. Methods Cell Biol.84, 425–444 (2008).
   PubMedGoogle Scholar
• Santarella RA, Skiniotis G, Goldie KN et al. Surface-decoration of microtubules by human tau. J. Mol. Biol.339(3), 539–553 (2004).
   PubMedGoogle Scholar
• Kar S, Fan J, Smith MJ, Goedert M, Amos LA. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J.22(1), 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of tau and the paired helical filaments of Alzheimer’s disease. Brain Pathol.17(1), 83–90 (2007).
   PubMed Web of Science ®Google Scholar
• Sillen A, Barbier P, Landrieu I et al. NMR investigation of the interaction between the neuronal protein tau and the microtubules. Biochemistry46(11), 3055–3064 (2007).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Smith MJ, Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett.437(3), 207–210 (1998).
   PubMed Web of Science ®Google Scholar
• Delobel P, Flament S, Hamdane M et al. Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation. J. Biol. Chem.277(11), 9199–9205 (2002).
   PubMedGoogle Scholar
• Fischer D, Mukrasch MD, von Bergen M et al. Structural and microtubule binding properties of tau mutants of frontotemporal dementias. Biochemistry46(10), 2574–2582 (2007).
   PubMed Web of Science ®Google Scholar
• Tatebayashi Y, Planel E, Chui DH et al. c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J.20(6), 762–764 (2006).
   PubMedGoogle Scholar
• Landrieu I, Lacosse L, Leroy A et al. NMR analysis of a Tau phosphorylation pattern. J. Am. Chem. Soc.128(11), 3575–3583 (2006).
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem.61(5), 1828–1834 (1993).
   PubMed Web of Science ®Google Scholar
• Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of b-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol.38(4), 643–648 (1995).
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Mulchahey JJ, Gudelsky GA. Quantification and localization of kainic acid-induced neurotoxicity employing a new biomarker of cell death: cleaved microtubule-associated protein-tau (C-tau). Neuroscience121(2), 399–409 (2003).
   PubMedGoogle Scholar
• Mori H, Hosoda K, Matsubara E et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett.186(2–3), 181–183 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson GV, Seubert P, Cox TM et al. The tau protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J. Neurochem.68(1), 430–433 (1997).
   PubMedGoogle Scholar
• Sjogren M, Davidsson P, Gottfries J et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord.12(4), 257–264 (2001).
   PubMed Web of Science ®Google Scholar
• Borroni B, Gardoni F, Parnetti L et al. Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging PMID: 17709155 (2007) (Epub ahead of print).
   Google Scholar
• Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry61(1), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Maccioni RB, Lavados M, Guillon M et al. Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol. Aging27(2), 237–244 (2006).
   PubMed Web of Science ®Google Scholar
• Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement. Geriatr. Cogn. Disord.17(4), 350–354 (2004).
   PubMedGoogle Scholar
• Hampel H, Burger K, Pruessner JC et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol.62(5), 770–773 (2005).
   PubMed Web of Science ®Google Scholar
• Hu YY, He SS, Wang X et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol.160(4), 1269–1278 (2002).
   PubMed Web of Science ®Google Scholar
• Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med.256(3), 224–234 (2004).
   PubMed Web of Science ®Google Scholar
• Sanchez-Juan P, Green A, Ladogana A et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology67(4), 637–643 (2006).
   PubMed Web of Science ®Google Scholar
• Goodall CA, Head MW, Everington D et al. Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. J. Neurol. Neurosurg. Psychiatr.77(1), 89–91 (2006).
   PubMed Web of Science ®Google Scholar
• Van Everbroeck B, Boons J, Cras P. Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease. Clin. Neurol. Neurosurg.107(5), 355–360 (2005).
   PubMedGoogle Scholar
• Vanderstichele H, De Vreese K, Blennow K et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin. Chem. Lab. Med.44(12), 1472–1480 (2006).
   PubMed Web of Science ®Google Scholar
• Vanmechelen E, Vanderstichele H, Hulstaert F et al. Cerebrospinal fluid tau and β-amyloid(1-42) in dementia disorders. Mech. Ageing Dev.122(16), 2005–2011 (2001).
   PubMedGoogle Scholar
• Grossman M, Farmer J, Leight S et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann. Neurol.57(5), 721–729 (2005).
   PubMed Web of Science ®Google Scholar
• Verbeek MM, Pijnenburg YA, Schoonenboom NS, Kremer BP, Scheltens P. Cerebrospinal fluid tau levels in frontotemporal dementia. Ann. Neurol.58(4), 656–657; author reply 657 (2005).
   PubMedGoogle Scholar
• Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin. Neurol.27(1), 22–31 (2007).
   PubMed Web of Science ®Google Scholar
• Brys M, Pirraglia E, Rich K et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging PMID: 17889968 (2007) (Epub ahead of print).
   Google Scholar
• Andersson ME, Sjolander A, Andreasen N et al. Kinesin gene variability may affect tau phosphorylation in early Alzheimer’s disease. Int. J. Mol. Med.20(2), 233–239 (2007).
   PubMedGoogle Scholar
• Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain129(Pt 11), 3035–3041 (2006).
   PubMed Web of Science ®Google Scholar
• Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M et al. Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol.6, 35 (2006).
   PubMed Web of Science ®Google Scholar
• Engelborghs S, De Vreese K, Van de Casteele T et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging PMID: 17428581 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Buerger K, Alafuzoff I, Ewers M et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain130(Pt 10), E82 (2007).
   PubMedGoogle Scholar
• Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc. Natl Acad. Sci. USA104(14), 5860–5865 (2007).
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol.25(9), 1035–1044 (2007).
   PubMed Web of Science ®Google Scholar
• Fulga TA, Elson-Schwab I, Khurana V et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.Nat. Cell Biol.9(2), 139–148 (2007).
   PubMed Web of Science ®Google Scholar
• Blard O, Feuillette S, Bou J et al. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum. Mol. Genet.16(5), 555–566 (2007).
   PubMed Web of Science ®Google Scholar
• Magnani E, Fan J, Gasparini L et al. Interaction of tau protein with the dynactin complex. EMBO J.26(21), 4546–4554 (2007).
   PubMedGoogle Scholar
• Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science319(5866), 1086–1089 (2008).
   PubMed Web of Science ®Google Scholar
• Mazanetz M, Fischer P. Untangling Tau hyperphosphorylation in drug design for neurodegenerative diseases.Nat. Rev. Drug Discov.6(6), 464–479).
   PubMedGoogle Scholar
• Bensemain F, Hot D, Ferreira S et al. Evidence for induction of the ornithine transcarbamylase expression in Alzheimer’s disease. Mol. Psychiatry PMID: 17893704 (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Luo MH, Leski ML, Andreadis A. Tau isoforms which contain the domain encoded by exon 6 and their role in neurite elongation. J. Cell. Biochem.91(5), 880–895 (2004).
   PubMedGoogle Scholar
• Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta1739(2–3), 91–103 (2005).
   PubMed Web of Science ®Google Scholar
• Janke C, Beck M, Holzer M, Bigl V, Arendt T. Analysis of the molecular heterogeneity of the microtubule-associated protein tau by two-dimensional electrophoresis and RT-PCR. Brain Res. Brain Res. Protoc.5(3), 231–242 (2000).
   PubMedGoogle Scholar
• Andreasen N, Gottfries J, Vanmechelen E et al. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and β-amyloid metabolism in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatr.71(4), 557–558 (2001).
   PubMedGoogle Scholar
• de Jong D, Jansen RW, Pijnenburg YA et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatr.78(9), 936–938 (2007).
   PubMed Web of Science ®Google Scholar
• Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data.BMC Med. Res. Methodol.6, 50 (2005).
   Google Scholar
• Bax L, Yu LM, Ikeda N, Moons KG. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med. Res. Methodol.7, 40 (2007).
   PubMed Web of Science ®Google Scholar